Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections

The approval marks a major milestone in the global fight against antimicrobial resistance

Wockhardt hosts Mother’s Day walkathon to promote women’s health and wellness

Women’s wellness initiative promoted preventive healthcare, fitness, and self-care awareness across the Mira Bhayandar community

Wockhardt reports FY26 net profit of Rs 317 crore, Board approves fundraising plan

Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance

Wockhardt’s breakthrough antibiotic Zaynich wins key regulatory nod in India

Wockhardt reports strong Q3 growth: revenue up 22%, EBITDA surges 72%

The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year

Wockhardt files marketing authorisation application for WCK 5222 with EMA

WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation

Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency

The accelerated review covers WCK 5222 for multiple critical infections

FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich

This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA

Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection

The NDA submission follows the successful completion of a pivotal Phase III global clinical trial

Wockhardt submits drug application to FDA for Zidebactam-Cefepime for treatment of serious Gram-negative infections

This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company